全文获取类型
收费全文 | 3287篇 |
免费 | 518篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 112篇 |
妇产科学 | 87篇 |
基础医学 | 447篇 |
口腔科学 | 46篇 |
临床医学 | 434篇 |
内科学 | 837篇 |
皮肤病学 | 39篇 |
神经病学 | 307篇 |
特种医学 | 87篇 |
外科学 | 405篇 |
综合类 | 99篇 |
一般理论 | 1篇 |
预防医学 | 395篇 |
眼科学 | 131篇 |
药学 | 226篇 |
中国医学 | 1篇 |
肿瘤学 | 145篇 |
出版年
2023年 | 27篇 |
2022年 | 44篇 |
2021年 | 53篇 |
2020年 | 51篇 |
2019年 | 51篇 |
2018年 | 66篇 |
2017年 | 45篇 |
2016年 | 52篇 |
2015年 | 54篇 |
2014年 | 74篇 |
2013年 | 94篇 |
2012年 | 150篇 |
2011年 | 170篇 |
2010年 | 92篇 |
2009年 | 72篇 |
2008年 | 141篇 |
2007年 | 157篇 |
2006年 | 147篇 |
2005年 | 148篇 |
2004年 | 144篇 |
2003年 | 125篇 |
2002年 | 120篇 |
2001年 | 96篇 |
2000年 | 87篇 |
1999年 | 106篇 |
1998年 | 33篇 |
1997年 | 43篇 |
1996年 | 23篇 |
1995年 | 29篇 |
1994年 | 33篇 |
1993年 | 35篇 |
1992年 | 82篇 |
1991年 | 91篇 |
1990年 | 81篇 |
1989年 | 81篇 |
1988年 | 89篇 |
1987年 | 64篇 |
1986年 | 60篇 |
1985年 | 58篇 |
1984年 | 48篇 |
1983年 | 54篇 |
1982年 | 37篇 |
1979年 | 29篇 |
1978年 | 31篇 |
1977年 | 29篇 |
1974年 | 42篇 |
1973年 | 26篇 |
1972年 | 23篇 |
1970年 | 25篇 |
1969年 | 28篇 |
排序方式: 共有3809条查询结果,搜索用时 15 毫秒
101.
Jonathan M Hill Mushabbar A Syed Andrew E Arai Tiffany M Powell Jonathan D Paul Gloria Zalos Elizabeth J Read Hanh M Khuu Susan F Leitman McDonald Horne Gyorgy Csako Cynthia E Dunbar Myron A Waclawiw Richard O Cannon 《Journal of the American College of Cardiology》2005,46(9):1643-1648
OBJECTIVES: Cytokine mobilization of progenitor cells from bone marrow may promote myocardial neovascularization with relief of ischemia. BACKGROUND: Patients with coronary artery disease (CAD) have low numbers of endothelial progenitor cells compared with healthy subjects. METHODS: Granulocyte colony-stimulating factor (G-CSF), 10 microg/kg/day for five days, was administered to 16 CAD patients. Progenitor cells were measured by flow cytometry; ischemia was assessed by exercise stress testing and by dobutamine stress cardiac magnetic resonance imaging. RESULTS: Granulocyte colony-stimulating factor increased CD34+/CD133+ cells in the circulation from 1.5 +/- 0.2 microl to 52.4 +/- 10.4 microl (p < 0.001), similar to the response observed in 15 healthy subjects (75.1 +/- 12.6 microl, p = 0.173). Indices of platelet and coagulation activation were not changed by treatment, but C-reactive protein increased from 4.5 +/- 1.3 mg/l to 8.6 +/- 1.3 mg/l (p = 0.017). Two patients experienced serious adverse events: 1) non-ST-segment elevation myocardial infarction (MI) 8 h after the fifth G-CSF dose, and 2) MI and death 17 days after treatment. At 1 month after treatment, there was no improvement from baseline values (i.e., reduction) in wall motion score (from 25.7 +/- 2.1 to 28.3 +/- 1.9, p = 0.196) or segments with abnormal perfusion (7.6 +/- 1.1 to 7.7 +/- 1.1, p = 0.916) and a trend towards a greater number of ischemic segments (from 4.5 +/- 0.6 to 6.1 +/- 1.0, p = 0.068). There was no improvement in exercise duration at 1 month (p = 0.37) or at 3 months (p = 0.98) versus baseline. CONCLUSIONS: Granulocyte colony-stimulating factor administration to CAD patients mobilizes cells with endothelial progenitor potential from bone marrow, but without objective evidence of cardiac benefit and with the potential for adverse outcomes in some patients. 相似文献
102.
Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex. 总被引:7,自引:2,他引:7
K M Brinkhous M S Read W A Fricke R H Wagner 《Proceedings of the National Academy of Sciences of the United States of America》1983,80(5):1463-1466
Botrocetin, originally called venom coagglutinin, is a Bothrops factor that causes aggregation of blood platelets in the presence of the von Willebrand component of the factor VIII macromolecular complex. The complex consists of a series of multimers with a molecular weight of about 1-20 x 10(6). Ristocetin, another agent that causes platelet aggregation dependent on von Willebrand factor, reacts with only the higher molecular weight multimers. We report on the reactivity of botrocetin in relation to the multimeric structure of the factor VIII complex. Several plasmas or plasma fractions with abnormal distribution of the multimeric sizes were examined, including variant von Willebrand disease type IIA with lack of the higher molecular weight forms, commercial antihemophilic factor concentrates with a preponderance of lower molecular weight forms, cryoprecipitate-free plasma containing mainly the smaller multimers, and a chromatographic fraction of plasma containing only the highest molecular weight polymers. Factor VIII-related antigen content was adjusted to 25-100%. All of the preparations lacking the high molecular weight forms caused prompt platelet aggregation with botrocetin, but none of them caused aggregation in the ristocetin test made isochronal with the botrocetin test. The very high molecular weight polymers were equally effective with botrocetin and ristocetin. These findings indicate that the Bothrops factor is reactive with a broad spectrum of high to low molecular weight forms of the factor VIII complex, suggesting that bioassays of von Willebrand factor with botrocetin should correlate better with immunoassays for factor VIII-related antigen and could reflect better the full platelet-aggregating function of the complex than do ristocetin determinations. 相似文献
103.
104.
105.
106.
107.
108.
109.
110.